Compare Blackstone Inc (BX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs Medpace Holdings Inc — how do they compare? Blackstone Inc trades at $145.2 (market cap $117.44B), while Medpace Holdings Inc trades at $601.56 (market cap $16.90B). The key difference: Blackstone Inc is far larger — about 6.9× Medpace Holdings Inc's market cap, and Blackstone Inc pays a 3.55% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| BX | MEDP | |
|---|---|---|
Market Cap | $117.44B | $16.90B |
Sector | Financials | Technology |
52-Week High | $188.68 | $620.59 |
52-Week Low | $102.12 | $393.42 |
Dividend Yield | 3.55% | — |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $141.67, up 3.31% today, near its consensus price target of $144.00. The stock shows strong bullish technical signals and has consistently beaten earnings estimates in recent quarters. Recent news highlights strategic acquisitions, including a stake in Air Canada's Aeroplan program and a $25.3 billion Australian home loan portfolio purchase from HSBC, signaling aggressive growth and diversification.
Outlook remains positive with robust revenue growth and high profitability, though elevated valuation ratios and overbought RSI levels suggest near-term caution. Key risks include market volatility and integration challenges from recent deals. Analyst consensus is strongly bullish, supporting a favorable long-term view.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
